Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2022

View Archived Issues

Immune suppressive glycoprotein-targeting MAb reported

CAP2 is increased in patients with AD and correlates with tau pathology

PP2B inhibition clears tau toxicity in experimental AD

Amyloid beta 42 impacts the expression of SPPL2B in AD

Anc80L65 vector combined with new surgical technique for hearing loss gene therapy

OLX-07010 shows promising efficacy in mouse models of tauopathy

TREM2 agonistic MAb attenuates tau burden and neurodegeneration

Researchers develop new murine model of AD

Sorrento reports findings with universal chimeric mRNA based COVID-19 vaccine

ALS Therapy Development Institute patents new compounds for ALS

Merck & Co. synthesizes new anti-HIV compounds

MagicMed Industries presents 5-HT2A receptor agonists

Incyte divulges new JAK2 inhibitors

Vertex Pharmaceuticals synthesizes new APOL1 inhibitors

Volastra collaborates with Bristol Myers Squibb to discover and develop oncology drug candidates

Grant supports Neuromagen's development of AGS-499 for ALS

Ixaka expands IP portfolio to allow use of TNP gene delivery platform across multiple areas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...